Canopy Growth Corporation (CGC)
USD 2.83
(-7.21%)
USD 2.83
(-7.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 799.82 Million USD | -52.37% |
| 2022 | 1.67 Billion USD | -15.39% |
| 2021 | 1.98 Billion CAD | -38.01% |
| 2020 | 3.2 Billion CAD | 90.59% |
| 2019 | 1.67 Billion CAD | 12.72% |
| 2018 | 1.49 Billion CAD | 669.9% |
| 2017 | 193.57 Million CAD | 207.91% |
| 2016 | 62.86 Million CAD | 221.15% |
| 2015 | 19.57 Million CAD | 355.84% |
| 2014 | 4.29 Million CAD | 225.28% |
| 2013 | 1.32 Million CAD | 12120.1% |
| 2012 | 10.8 Thousand CAD | 18.21% |
| 2011 | 9140.00 CAD | 38.23% |
| 2010 | 6612.00 CAD | -13.39% |
| 2009 | 7634.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 550.43 Million USD | -5.82% |
| 2023 Q4 | 590.42 Million USD | -27.56% |
| 2023 Q3 | 815.08 Million USD | -11.28% |
| 2023 Q2 | 918.76 Million USD | -31.59% |
| 2023 Q1 | 1.34 Billion USD | -20.01% |
| 2023 FY | 799.82 Million USD | -52.37% |
| 2022 Q1 | 1.83 Billion CAD | -7.56% |
| 2022 FY | 1.67 Billion USD | -15.39% |
| 2022 Q4 | 1.67 Billion USD | 6.24% |
| 2022 Q3 | 1.58 Billion CAD | -9.08% |
| 2022 Q2 | 1.73 Billion CAD | -5.25% |
| 2021 Q3 | 2.09 Billion CAD | -3.6% |
| 2021 Q2 | 2.17 Billion CAD | -19.0% |
| 2021 Q4 | 1.98 Billion CAD | -5.38% |
| 2021 Q1 | 2.68 Billion CAD | -16.1% |
| 2021 FY | 1.98 Billion CAD | -38.01% |
| 2020 Q3 | 2.01 Billion CAD | 41.74% |
| 2020 Q1 | 1.58 Billion CAD | -5.73% |
| 2020 Q2 | 1.42 Billion CAD | -10.29% |
| 2020 FY | 3.2 Billion CAD | 90.59% |
| 2020 Q4 | 3.2 Billion CAD | 59.0% |
| 2019 Q4 | 1.67 Billion CAD | -33.24% |
| 2019 Q3 | 2.51 Billion CAD | -3.32% |
| 2019 Q1 | 2.75 Billion CAD | 84.68% |
| 2019 FY | 1.67 Billion CAD | 12.72% |
| 2019 Q2 | 2.6 Billion CAD | -5.44% |
| 2018 FY | 1.49 Billion CAD | 669.9% |
| 2018 Q4 | 1.49 Billion CAD | 22.52% |
| 2018 Q2 | 1.13 Billion CAD | 27.91% |
| 2018 Q3 | 1.21 Billion CAD | 7.11% |
| 2018 Q1 | 887.85 Million CAD | 358.65% |
| 2017 Q2 | 67.11 Million CAD | 10.38% |
| 2017 Q4 | 193.57 Million CAD | 157.11% |
| 2017 FY | 193.57 Million CAD | 207.91% |
| 2017 Q1 | 60.8 Million CAD | -3.28% |
| 2017 Q3 | 75.29 Million CAD | 12.18% |
| 2016 Q2 | 24.58 Million CAD | 23.84% |
| 2016 FY | 62.86 Million CAD | 221.15% |
| 2016 Q4 | 62.86 Million CAD | 115.74% |
| 2016 Q3 | 29.14 Million CAD | 18.53% |
| 2016 Q1 | 19.85 Million CAD | 1.41% |
| 2015 Q4 | 19.57 Million CAD | 11.87% |
| 2015 Q2 | 11.55 Million CAD | 68.99% |
| 2015 FY | 19.57 Million CAD | 355.84% |
| 2015 Q1 | 6.83 Million CAD | 7.43% |
| 2015 Q3 | 17.49 Million CAD | 51.44% |
| 2014 Q1 | 3.13 Million CAD | 12.99% |
| 2014 Q3 | 4.29 Million CAD | 96.38% |
| 2014 Q2 | 2.18 Million CAD | -30.3% |
| 2014 Q4 | 6.36 Million CAD | 48.21% |
| 2014 FY | 4.29 Million CAD | 225.28% |
| 2013 Q3 | 2438.00 CAD | -77.94% |
| 2013 Q1 | 10.8 Thousand CAD | 535.53% |
| 2013 FY | 1.32 Million CAD | 12120.1% |
| 2013 Q2 | 11.05 Thousand CAD | 2.31% |
| 2013 Q4 | 2.77 Million CAD | 113794.75% |
| 2012 Q4 | 1700.00 CAD | 19.47% |
| 2012 FY | 10.8 Thousand CAD | 18.21% |
| 2012 Q1 | 9140.00 CAD | 41.05% |
| 2012 Q2 | 6500.00 CAD | -28.88% |
| 2012 Q3 | 1423.00 CAD | -78.11% |
| 2011 Q4 | 6480.00 CAD | -40.77% |
| 2011 FY | 9140.00 CAD | 38.23% |
| 2011 Q1 | 6612.00 CAD | 25.87% |
| 2011 Q2 | 10.2 Thousand CAD | 54.3% |
| 2011 Q3 | 10.94 Thousand CAD | 7.23% |
| 2010 Q2 | 3630.00 CAD | -52.45% |
| 2010 FY | 6612.00 CAD | -13.39% |
| 2010 Q4 | 5253.00 CAD | 34.66% |
| 2010 Q3 | 3901.00 CAD | 7.47% |
| 2010 Q1 | 7634.00 CAD | -75.34% |
| 2009 FY | 7634.00 CAD | 0.0% |
| 2009 Q4 | 30.96 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Theratechnologies Inc. | 98.63 Million USD | -710.859% |
| Harrow Health, Inc. | 241.75 Million USD | -230.843% |
| Dynavax Technologies Corporation | 375.02 Million USD | -113.272% |
| Biofrontera Inc. | 23.13 Million USD | -3356.601% |
| Cronos Group Inc. | 43.73 Million USD | -1728.749% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -9034.571% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 2.147% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1550.992% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -3712.653% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1423.002% |
| Radius Health, Inc. | 804.29 Million USD | 0.555% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -5715.063% |
| DURECT Corporation | 30.4 Million USD | -2530.478% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1779.99% |
| Safety Shot Inc | 3.89 Million USD | -20450.204% |
| Phibro Animal Health Corporation | 725.54 Million USD | -10.238% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -8596.932% |
| Alvotech | 1.88 Billion USD | 57.515% |
| Assertio Holdings, Inc. | 148.41 Million USD | -438.906% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -64.079% |
| Rockwell Medical, Inc. | 30.88 Million USD | -2489.933% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -12927.282% |
| Procaps Group S.A. | 462.06 Million USD | -73.098% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -484.363% |
| SCYNEXIS, Inc. | 55.45 Million USD | -1342.422% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -784.966% |
| Viatris Inc. | 27.21 Billion USD | 97.061% |
| OptiNose, Inc. | 194.33 Million USD | -311.569% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1279.545% |
| Tilray Brands, Inc. | 892.11 Million USD | 10.346% |
| PetIQ, Inc. | 645.22 Million USD | -23.96% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -12927.282% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 21.54% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -21103.462% |
| Alimera Sciences, Inc. | 107.35 Million USD | -645.033% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 15.62% |
| Silver Spike Investment Corp. | 3 Million USD | -26473.685% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -42085.536% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -341.009% |
| Journey Medical Corporation | 56.49 Million USD | -1315.641% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -3652.259% |
| Alpha Teknova, Inc. | 38.55 Million USD | -1974.714% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -11283.76% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -263.887% |
| PainReform Ltd. | 2.69 Million USD | -29622.148% |
| Cosmos Health Inc. | 30.25 Million USD | -2543.822% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -361.294% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -5604.058% |
| Embecta Corp. | 2.03 Billion USD | 60.718% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -364264.135% |
| Talphera, Inc. | 6.29 Million USD | -12615.787% |
| Pacira BioSciences, Inc. | 704.25 Million USD | -13.57% |
| Incannex Healthcare Limited | 5.83 Million USD | -13619.091% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -9320.176% |
| Shineco, Inc. | 47.6 Million USD | -1580.241% |
| Procaps Group, S.A. | 462.06 Million USD | -73.098% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -69.572% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -387.98% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 4.242% |
| Alvotech | 1.88 Billion USD | 57.515% |
| Hempacco Co., Inc. | 18.82 Million USD | -4149.314% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -363.397% |
| Bright Green Corporation | 6.43 Million USD | -12323.273% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -21.04% |
| Kamada Ltd. | 109.96 Million USD | -627.321% |
| Indivior PLC | 1.95 Billion USD | 59.01% |
| Evoke Pharma, Inc. | 9.64 Million USD | -8189.968% |
| Flora Growth Corp. | 17.22 Million USD | -4544.193% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -9320.176% |
| Evolus, Inc. | 209.68 Million USD | -281.437% |
| HUTCHMED (China) Limited | 536.38 Million USD | -49.113% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 8.434% |
| Akanda Corp. | 12.66 Million USD | -6213.286% |